Mechanism of intravenous immunoglobulin therapy for severe hand-foot-mouth disease: a review

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 27, Issue 5, 2011, Pages 712-716

  Cao, Ruiyuan ^a   Han, Jianfeng ^a   Qin, Ede ^a   Qin, Chengfeng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Enterovirus type 71; Hand foot mouth disease (HFMD); Intravenous immunoglobulin (IVIG); Neutralization antibody

Indexed keywords

IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ENTEROVIRUS; HAND FOOT AND MOUTH DISEASE; HUMAN; IMMUNOLOGY; PASSIVE IMMUNIZATION; REVIEW; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS;

ENTEROVIRUS; HUMAN ENTEROVIRUS 71;

EID: 79960996355     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Zhou B P. Enterovirus Type 71 and Hand-Foot-and-Mouth Disease. Beijing: People's Medical Publishing House, 2009.
2. Li L J. Hand-Foot-and-Mouth Disease. Hangzhou: Zhejiang Science & Technology Publishing House, 2008.
3. Yang F, Ren L, Xiong Z, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol, 2009, 47(7): 2351-2352.
4. Ooi M H, Wong S C, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol, 2010, 9(11): 1097-1105.
5. Wang S M, Liu C C. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther, 2009, 7(6): 735-742.
6. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity, 2009, 42(6): 553-560.
7. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol, 2006, 6(4): 528-534.
8. Hemming V G. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol, 2001, 8(5): 859-863.
9. Mouthon L, Lortholary O. Intravenous immunoglobulins in infectious diseases: where do we stand? Clin Microbiol Infect, 2003, 9(5): 333-338.
10. Hemming V G, Prince G A, Groothuis J R, et al. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev, 1995, 8(1): 22-33.
11. Bayry J, Lacroix-Desmazes S, Kazatchkine M D, et al. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci, 2004, 25(6): 306-310.
12. Brunetti L, DeSantis E R. Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm, 2008, 65(2): 132-137.
13. Pasic S, Jankovic B, Abinun M, et al. Intravenous immunoglobulin prophylaxis in an echovirus 6 and echovirus 4 nursery outbreak. Pediatr Infect Dis J, 1997, 16(7): 718-720.
14. Abzug M J, Keyserling H L, Lee M L, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis, 1995, 20(5): 1201-1206.
15. McKinney R E Jr, Katz S L, Wilfert C M. Chronic enteroviral meningoencephalitis in a gamma globulinemic patients. Rev Infect Dis, 1987, 9(2): 334-356.
16. Johnston J M, Overall J C Jr. Intravenous immunoglobulin in disseminated neonatal echovirus 11 infection. Pediatr Infect Dis J, 1989, 8(4): 254-256.
17. Valduss D, Murray D L, Karna P, et al. Use of intravenous immunoglobulin in twin neonates with disseminated coxsackie B1 infection. Clin Pediatr (Phila), 1993, 32(9): 561-563.
18. Chen Z M. Analysis of treatment efficacy of hand, foot and mouth disease complicated with encephalitis using human serum gamma globulin. Chin J Misdiagn, 2008, 8(33): 8112-8113.
19. Zhou G Z. The curative effects of intravenous immunoglobulin on hand-foot-mouth disease. J Huaihai Med, 2009, 27(5): 393-394.
20. Foo D G, Alonso S, Chow V T, et al. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect, 2007, 9(11): 1299-1306.
21. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/ 201004/46884.htm.
22. http://www.moh.gov.cn/ publicfiles/business/htmlfiles/mohncwsgls/s3581/ 201007/48296.htm.
23. Cao R, Han J, Deng Y, et al. Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin Infect Dis, 2010, 50(1): 125-126.
24. Huang C C. Neurologic complications of enterovirus 71 infection in children: lessons lfrom this Taiwan epidemic. Acta Paediatr Taiwan, 2001, 42(1): 5-7.
25. Nagington J, Gandy G, Walker J, et al. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. Lancet, 1983, 2(8347): 443-446.
26. Wang S M, Lei H Y, Huang M C, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol, 2006, 37(1): 47-52.
27. Wang S M, Lei H Y, Huang K J, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: Roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis, 2003, 188(4): 564-570.
28. Kaneko Y, Nimmerjahn F, Ravetch J V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 2006, 313(5787): 670-673.
29. Wang S M, Ho T S, Shen C F, et al. Enterovirus 71, one virus and many stories. Pediatr Neonatol, 2008, 49(4): 113-115.
30. Lin T Y, Hsia S H, Huang Y C, et al. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis, 2003, 36(3): 269-274.
31. Yang S Z, Du P F. The curative effect of γ-globulin combined with methylprednisolone on hand foot and mouth disease in children complicated nervous system damage. Chin Pediatr Emerg Med, 2009, 16(2): 168-169.
32. Chen C, Chen X P, Wu S G. Clinical observation of shock treatment for hand, foot and mouth disease using ribavirin combined with high dose gamma globulin. J Hebei Med, 2009, 15(7): 834-836.
33. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev, 2007, 6(4): 257-259.
34. Wang S M, Chen I C, Su L Y, et al. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol, 2010, 17(10): 1517-1523.